Has Henrik Wilms, MD received payments from drug or device companies?

Yes. Drug and device makers reported $116,648 in general payments to Henrik Wilms, MD across 330 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Henrik Wilms, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Henrik Wilms, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Henrik Wilms, MD

Neurology · Lubbock, TXNPI 1770850513

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $80,249 of the $116,648 with a category attached, or 68.8%. Teva Pharmaceuticals USA, Inc. accounts for 68.2% of it on its own, with 14 other manufacturers making up the rest. Reporting peaked in 2023 at $38,545 and has fallen 71.4% since, to $11,037 in 2025. Among neurology clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$116,648in general payments, 2019–2025

Across 330 payments — averaging $353.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Teva Pharmaceuticals USA, Inc.$80K
Neurocrine Biosciences, Inc.$35K
Medtronic$999
Abbott$301
Sanofi$252
Insightec,inc$146
plus $432 from 9 others

What the payments were for

Consulting fees$19,12316%
Speaking & faculty fees$80,24969%
Travel & lodging$10,3639%
Food & beverage$6,6616%
Education$2520%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Teva Pharmaceuticals USA, Inc.	240	$79,516
Neurocrine Biosciences, Inc.	59	$35,001
Medtronic	11	$999
Abbott	4	$301
Sanofi	3	$252
Insightec,inc	1	$146
Kyowa Kirin, Inc.	1	$116
Bristol Myers Squibb	1	$93
Biogen	3	$64
EMD Serono, Inc.	2	$47
SK Life Science, Inc.	1	$27
Lundbeck LLC	1	$26
Eisai Inc.	1	$25
Amgen	1	$19
Acorda Therapeutics, Inc	1	$15

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$116,648 in reported general payments places this provider in the 95th percentile of 1,246 neurology providers in Texas.

See all neurology providers in Texas →

Medicare billing

Part B allowed, 2024

$61,878

Medicare patients

317

Services billed

549

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
NeuproRotigotine	13	$15,255
Carbidopa-Levodopa-EntacaponeCarbidopa/Levodopa/Entacapone	55	$10,947
Carbidopa-LevodopaCarbidopa/Levodopa	189	$3,908
Primidone	123	$2,602
Rasagiline Mesylate	18	$1,683
Carbidopa-Levodopa ErCarbidopa/Levodopa	19	$1,337
Ropinirole Hcl	48	$1,215
Selegiline Hcl	13	$1,194
AmantadineAmantadine Hcl	21	$974
Levetiracetam	28	$646
Gabapentin	53	$640
Topiramate	22	$280
Pramipexole DihydrochloridePramipexole Di-Hcl	25	$252
Baclofen	13	$198
Clonazepam	22	$150

Paid to pharmacies, not to this prescriber.

Other neurology in Lubbock

Mirla AvilaLubbock$1.3M
Katie HendleyLubbock$203K
Ann BassSan Antonio$1.7M
William OndoHouston$1.4M
Nirav PavasiaDallas$1.4M
Michael SoileauGeorgetown$1.2M
Pankaj SatijaHouston$1.1M
Annette HowardHouston$826K
Benjamin GreenbergDallas$773K
Annette OkaiPlano$730K

See the full list for Texas →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →